Vectavir Cream 2 gr 1%

€13.49
Tax included
Minsan
032155018
100% secure payments
Hurry up! Only 40 item(s) left in Stock!
Quantity

WARNINGS
The cream should only be applied to the lesions of the lips and around the mouth. Application on mucous membranes (e.g. in the eyes, mouth or nose or on the genitals) is not recommended. Particular care should be taken to avoid application in or near the eyes. Severely immunocompromised patients (e.g. patients with AIDS or who have undergone a bone marrow transplant) should be encouraged to consult a physician if therapy is indicated. oral. The product contains cetostearyl alcohol and propylene glycol.
PHARMACOTHERAPEUTIC CATEGORY
Topical chemotherapy.
STORAGE
Do not store above 30 degrees C; do not freeze.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance penciclovir, famciclovir or to any of the excipients listed; children under the age of 12.
NAME
VECTAVIR 1% CREAM
EXCIPIENTS
Solid paraffin; liquid paraffin; cetostearyl alcohol; propylene glycol; cetomacrogol 1000; purified water.
SIDE EFFECTS
The drug was well tolerated in human studies. Experience from clinical trials has shown that there is no difference in the frequency or type of adverse reactions between the drug and placebo. The most common events are adverse events in the application area. Adverse reactions are listed below by organ system, class and frequency. The frequencies are defined as follows: very common (> 1/10); common (> 1/100 to <1/10); uncommon (> 1 / 1,000 to <1/100); rare (> 1 / 10,000 to <1 / 1,000); very rare (<1 / 10,000), not known. General disorders and administration site conditions. Common: Application site reactions (including skin burning sensation, skin pain, hypoesthesia). Post-marketing surveillance revealed the following adverse events (all reactions were either localized or general). It is difficult to define a frequency for post-marketing adverse events and therefore the events are listed with unknown frequency. Immune system disorders: hypersensitivity, urticaria. Skin and subcutaneous tissue disorders: allergic dermatitis (including rash, itching, blistering and edema). The reporting of suspected adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product.
PREGNANCY AND BREASTFEEDING
When the cream is used in pregnant women, it is unlikely that there is any cause for concern for adverse effects as systemic absorption of penciclovir after topical application of the drug has been found to be minimal. Since the safety of penciclovir in pregnant women has not been established, the drug should be used, on medical advice, during pregnancy or by mothers who are breastfeeding, only if the potential benefits outweigh the potential risks associated with the treatment. When the cream is used in women who are breastfeeding, it is unlikely that there is any cause for concern about adverse effects as systemic absorption of penciclovir after topical application of the product has been found to be minimal. There is no information on the excretion of penciclovir in human milk.
INDICATIONS
Treatment of herpes labialis.
INTERACTIONS
Experience in clinical trials has not identified interactions resulting from the concomitant administration of topical or systemic drugs and the medicinal product.
DOSAGE
Adults (including the elderly) and children over 12 years of age: the drug should be applied at intervals of about 2 hours throughout the day. Treatment, to be continued for 4 days, should be started as soon as possible, at the first sign of infection. However, even in patients who start therapy later, the product has been shown to be effective in accelerating wound healing, reducing associated pain and shortening the time to viral spread. Instructions for application: the medicine must be applied, in an amount suitable for the size of the area to be treated, with a clean finger or with a disposable applicator that must be discarded after use [for packs containing applicators]. >> Pediatric population. Children (under 12 years of age): the use of the product is not recommended in children under 12 years of age due to a lack of data on safety and / or efficacy.
ACTIVE PRINCIPLES
Penciclovir.
032155018
40 Items

Specific References

chat Comments (0)
No customer reviews for the moment.

Vectavir Cream 2 gr 1%

€13.49